COMP <GO>
BIO vs BRKR // ALTMAN Z-SCORE & DEBT/EQUITY
Bio-Rad Laboratories Inc. (NYSE) VS. Bruker Corporation (NASDAQ) • 15-METRIC TALLY: BIO 10
— BRKR 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BIO
LAST: $366.16 (-1.62%) • MKT CAP: $9.95B
balance-sheet
3.59
LAST: $55.69 (-2.42%) • MKT CAP: $8.70B
balance-sheet
2.81
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. BRKR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | BRKR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 45.90% | +6.00 | BIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | 1.30% | -0.80 | BRKR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | 75.7x | -15.30 | BIO | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 0.46% | +3.18 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | 2.00% | -0.20 | BRKR | /operating-margins <GO> |
| Net Profit Margin | 29.40% | -0.20% | +29.60 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 2.10% | -1.40 | BRKR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | BRKR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.59 | 2.81 | +0.78 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | BIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 45.8 | +4.30 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.97 | +0.07 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 22.0x | -9.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.95B | $8.70B | $1.26B | BIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | BRKR REV | BIO GROSS % | BRKR GROSS % | BIO FCF | BRKR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $3.44B | 51.9% | 45.9% | $374.6M | $43.3M |
| FY 2024 | $2.57B | $3.37B | 53.7% | 49.0% | $289.6M | $136.0M |
| FY 2023 | $2.67B | $2.96B | — | — | $254.7M | $216.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
BRKR // BETA 0.97